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Adrenocortical carcinoma (ACC) is an aggressive cancer characterized by poor 
survival. Apart from radical surgery, there is a limited range of therapeutic options and 
mitotane remains the cornerstone of medical treatment of ACC in either adjuvant or 
palliative settings. The aim of adjuvant mitotane therapy is to reduce the risk of ACC 
recurrence following surgical removal of the tumor. Use of mitotane in an adjuvant 
setting is off-label, but the recent guidelines endorsed by the European Society of 
Endocrinology (ESE) and the European Network for the Study of Adrenal Tumors 
(ENSAT) recommend it in ACC patients at high risk of recurrence. The palliative use of 
mitotane for treatment of advanced ACC aims at controlling tumor progression and, 
when present, hormone secretion. In this clinical setting, mitotane is used in 
association with chemotherapy to treat the more aggressive forms, while mitotane 
monotherapy is reserved for less progressive ACC. Many years after its introduction in 
clinical practice, there are still uncertainties surrounding the use of this old drug and 
the derived benefits. Moreover, physicians who use mitotane should recognize and 
manage the systemic effects of the drug that need a complex supporting therapy. 
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Introduction 
Adrenocortical carcinoma (ACC) is extremely rare, with a reported incidence of about 
two cases per million per year. ACC is more frequently detected in women (55–60%) 
and in the fourth and fifth decades; however, any age including childhood can be 
affected (1, 2).  
ACC is an aggressive cancer with an overall 5-year survival rate between 16% and 
47% (3, 4). Prognosis is mainly influenced by tumor stage, being the 5-year survival 
81, 61, 50, and 13%, respectively, from stage I to stage IV, and the possibility to 
remove completely the tumor, which also depends on ACC stage at diagnosis (5). 
However, ACC is a heterogeneous disease and survival may show considerable 
variability at any stage depending on molecular, pathological and clinical factors that 
have only been partially elucidated (6). 
One of the factors influencing the clinical phenotype of ACC patients is the functional 
activity of the tumor, which may result in different endocrine syndromes (3, 4, 6). 
Manifestations of adrenal steroid hormone excess represent a common presentation 
of ACC that may be found in up to 60% of cases (3, 4, 7). Patients with non-
functioning ACC present with back or abdominal pain, nausea, vomiting, or less 
frequently fever and weigh loss. In an increasing number of patients, ACC is 
discovered serendipitously, due to the widespread application of high-resolution cross-
sectional scans (8).   
A limited range of therapeutic options is available for ACC. The rarity and 
aggressiveness of the tumor have hindered progress in treatment that remains mainly 
based on surgery. Surgery is usually the first and most effective therapeutic strategy, 
while survival is poor when surgical removal of ACC is unfeasible (9-11). Complete 
surgery may be curative; however, the odds that ACC may recur after surgery are high 
(11, 12). Tumor recurrence can be explained with technical failure of surgery leading 
to tumor rupture or spillage, but is also frequently observed after microscopically 
radical (R0) operations done by skilled surgeons (11, 12). Therefore, a sound 
treatment strategy should include in principle an adjuvant treatment to avoid tumor 
recurrence. Administration of mitotane has been the most followed adjuvant approach 
in clinics, albeit mitotane is formally approved by regulatory agencies for treatment of 
advanced ACC (2, 3).   
In patients with inoperable or metastatic disease, mitotane is the mainstay of treatment 
and can be used as a single agent or in combination with classic cytostatic drugs. A 
key concept of mitotane treatment in patients with advanced/metastatic ACC is that 
disease responses are mainly seen in patients whose plasma mitotane concentrations 
are between 14 and 20 mg/L (2-4, 6).  
Owing to the latency to attain the therapeutic range, mitotane monotherapy may best 
suited for patients with a low tumor burden and less rapid disease. For ACC showing 
an aggressive disease course, or with many metastatic sites, cytotoxic chemotherapy 
in association with mitotane may be more reasonable, particularly when ACC is 
progressing on mitotane therapy (2-4, 6). The polychemotherapy regimen EDP-M, 
including etoposide, doxorubicin, cisplatin and mitotane, represents the current 
standard of chemotherapy for advanced ACC, being the only treatment strategy 
supported by a randomized controlled trial (13). 
The first report of the capability of mitotane to destroy the zona fasciculata and zona 
reticularis in the adrenal glands was published in 1949, showing that mitotane 
treatment in dogs induced a marked reduction of glucocorticoids and 17-
hydroxycorticosteroids either in basal conditions or after ACTH stimulation (14, 15). 
Following this observation, it was found that mitotane is able to inhibit gene expression 
of a variety of enzymes of the steroidogenetic pathway (15). This leads to a 
remarkable inhibition of adrenal steroid production; thus, mitotane may ameliorate 
signs and symptoms of cortisol excess, and this adrenolytic drug has been used as a 
medical treatment of all causes of Cushing’s syndrome (16, 17). 
More than 50 years after the introduction in clinical practice of mitotane, we still do not 
know precisely its mechanism of action, what is the optimal use of this old drug and 
what we may expect in terms of efficacy. Mitotane is currently used both in 
postoperative adjuvant and palliative (advanced) settings; however, no data from 
randomized prospective trials on mitotane as monotherapy are available to guide 
management. 
Mechanism of action of mitotane 
Mitotane, [1,1-dichlorodiphenildichloroethane (o,p’-DDD)], a parent compound of the 
insecticide dichlorodiphenyltrichloroethane (DDT), is the only drug approved by the 
FDA and EMEA for ACC treatment (2-4, 6). Mitotane has a profound effect on 
steroidogenesis (16, 17) that may be explained with the inhibition of gene transcription 
of many steroidogenic enzymes (18-20). Steroidogenic acute regulatory protein (StAR) 
and CYP11A1, which are involved in the rate-limiting step of steroidogenesis, are most 
sensitive to mitotane (19). The intracellular targets of mitotane remains to be identified; 
however, mitotane has been found to produce mitochondrial damage that activates an 
apoptotic process involving caspase 3 and caspase 7 activities (20). Studies showed 
that mitotane is able to interfere with the mitochondrial respiratory chain function 
complex IV (cytochrome coxidase) and to induce morphologic fragmentation of the 
mitochondrial membranes that are required for respiratory chain activity and 
presumably steroidogenesis (21). 
Moreover, mitotane was found to be a strong inducer of CYP3A4 activity leading to 
glucocorticoid inactivation and a consequent sharp rise in 6β-hydroxycortisol urinary 
excretion. It was calculated that mitotane is able to inactivate 50% of administered 
hydrocortisone, thus explaining why patients on mitotane do need higher doses of 
steroids for an effective replacement (22).  
Study demonstrated that mitotane is an inhibitor of sterol-O-acyl-transferase 1 
(SOAT1) leading to accumulation of free cholesterol that becomes toxic for the cell. 
The fact that SOAT1 is predominantly expressed by the adrenals explains why 
mitotane, by inhibiting SOAT1, down-regulates steroidogenesis and exerts a cytotoxic 
effect due to lipid-induced endoplasmic reticulum stress. In a small number of ACC 
tissues, SOAT1 expression correlated with the response to mitotane treatment, i.e. low 
SOAT1 expression was associated with poor response (23).  
 
Practice Point 
• Mitotane interferes with mitochondrial function reducing cell viability and function 
(hormone secretion). 
Research Agenda 
• The molecular targets of mitotane need to be elucidated to get a potential 
predictor of response that could be searched for in tumor cells. 
 
Mitotane in the adjuvant setting 
The best outcome for ACC patients is dependent on the possibility of a radical surgery. 
Therefore, surgery must be performed by an experienced surgical team, in high 
volume centers (12, 24), with the goal of achieving R0 resection (microscopically free 
margins). The risk for recurrence is lower for patients who undergo surgery by expert 
surgeons (24), although the risk is never abolished. More than 50% of the tumors that 
have been completely extirpated are doomed to relapse (11, 24-27), and most patients 
with ACC recurrence experience further tumor progression and eventually die. 
Surgical failure is not the only reason for recurrence, given that even stage I-II ACC 
recurs frequently. Several potential predictive factors of recurrence in radically 
resected ACC have been identified (28-31), but the issue of defining prognostic factors 
is complicated by the great variability of clinical presentation and biological 
heterogeneity of ACC.  
The significant propensity of ACC to recur provides a strong rationale for adjuvant 
therapy following ACC removal. The pioneering work by Schteingart (32) prompted 
many researches to consider the use of post-operative mitotane as adjuvant therapy; 
however, evidence is still conflicting for a variety of reasons. 
First, most studies had limited statistical power (26, 33-35). Second, many studies did 
not include a concomitant matched control group of untreated patients (26, 32, 34-37), 
whereas in some series a number of patients underwent multiple adjuvant treatments 
(38). In addition, the definition of recurrence-free survival (RFS) has not been uniform, 
and the duration of response has been sometimes unclear. Finally, all studies but one 
(32) were retrospective and employed different formulations of mitotane at doses 
ranging from 3 to 20 g daily, which were given for different periods (38).  
Mitotane has a narrow therapeutic index and can cause significant toxicity and this 
does not make mitotane an ideal drug to treat patients free of disease. The potential of 
severe toxicity coupled with a controversial literature (26, 33, 37-43) made adjunctive 
treatment with mitotane less appealing until the last 10 years.  
Interest in adjuvant mitotane was resumed in 2007, when we published a retrospective 
analysis involving a large cohort of 177 ACC patients, followed for up to 10 years at 
different institutions in Italy and Germany. We found that patients treated with adjuvant 
mitotane had a significantly survival advantage compared with patients left untreated 
following surgery (44). The study challenged the concept that adjuvant mitotane 
therapy is unfeasible and ineffective; a favorable effect was achieved with low doses of 
mitotane (1–5 g per day), which were associated with acceptable toxicity (44). 
Conversely, severe and disabling toxicity was observed in previous studies employing 
high doses of mitotane (38). The retrospective nature of our study, however, does not 
allow concluding definitively that adjuvant mitotane treatment is beneficial. Arguments 
against adjuvant mitotane are mainly based on the methodological flaws of a 
retrospective analysis, toxicity and complexity of mitotane treatment, and lack of 
factors predicting response to treatment (45).  
Novel evidence on the value of adjuvant mitotane has been published in the last years 
(46-48). A surgical study from the M.D. Anderson Cancer Center showed that the lack 
of adjuvant mitotane treatment was a factor predicting a higher risk of recurrence, 
despite the claim that a state-of-the-art surgical approach may avoid use of adjuvant 
mitotane (46). A study from Germany found that survival was improved in patients with 
stage II ACC managed at expert centers, in which adjuvant mitotane was used more 
frequently than in the community (47). A retrospective analysis from the University of 
Michigan reported on a large cohort of patients from a single center that mitotane 
treatment was associated with a significantly improved RFS. Mitotane was of benefit 
despite the fact that patients treated adjuvantly had a worse risk profile than the 
control group. A positive interaction between mitotane therapy and local radiotherapy 
was found, thus introducing the concept of a combined treatment (48).  
The ESE-ENSAT guidelines suggest considering radiation in addition to mitotane 
therapy as an adjuvant measure on an individualized basis therapy in patients with R1 
or Rx resection, or in stage III ACC (49).  
Our group has updated the follow-up of the patient cohorts included in the 2007 study 
with almost 10 years of additional observation, confirming that adjuvant mitotane 
treatment was associated with a significant benefit in terms of RFS regardless of the 
hormone secretory status (50). Median RFS was 42 months in the adjuvant group 
compared with 17 months in control group 1 (p<0.001) and 26 months in control group 
2 (p<0.005). Mitotane-treated patients had a significant benefit in overall survival (OS) 
in comparison with the control group 1, while the difference in OS just failed to reach 
statistical significance with the control group 2 (50). In this study, landmark analysis 
was employed to circumvent the immortal-time bias that is a common confounder of 
this type of studies. Despite its retrospective nature, this study remains the most 
informative one on the topic and represents a reference for decision making on 
adjuvant therapy. The advantage of our study compared to others is that treatment 
assignment was center-specific (i.e. all patients of a given center were treated or not 
treated) and not based on patient characteristics. In most studies, presence of 
unfavorable prognostic characteristics was a factor supporting the decision to give 
adjuvant mitotane and this have introduced confounding by indication since mitotane-
treated patients had higher risk of recurrence at baseline than untreated patients.  
Literature is conflicting and there is also recent evidence of a relative ineffectiveness of 
adjuvant mitotane. A retrospective analysis of the outcomes of 207 ACC patients, who 
underwent resection at 13 surgical centers in the United States, reported that adjuvant 
mitotane use was associated with decreased RFS (51). The difference with our results 
may be readily explained by the selection to mitotane treatment of patients at 
unfavorable prognosis in that study. The patients who were treated with mitotane had 
a higher frequency of stage IV metastatic tumors and, indeed, chemotherapy was 
frequently associated to mitotane therapy. Also, the frequency of cortisol excess, 
another negative prognostic factor, was higher in the mitotane group (51). 
Efficacy of adjuvant mitotane treatment has been the subject of two recent meta-
analyses that were able to retrieve only 6 and 5 studies, respectively, fulfilling the 
quality criteria of sufficient patient number, presence of a concomitant control group of 
untreated patients and reporting of baseline patient characteristics. Due to the variable 
inclusion criteria and different study procedures, a remarkable heterogeneity between 
studies was apparent in both meta-analyses that were not able to identify predictors of 
response to adjuvant mitotane (49, 52). Both meta-analyses, however, concluded that 
adjuvant mitotane was associated with a significant prolongation of OS, and in one 
study also RFS was significantly prolonged (52).  
The ESE - ENSAT guidelines on the management of ACC suggest adjuvant mitotane 
treatment for patients at high risk of recurrence following complete tumor extirpation, 
although recognizing the low level of evidence of this recommendation. Adjuvant 
mitotane remains an option to be discussed on individual basis for patients at low risk 
of recurrence (49).   
We have recently reviewed our experience with adjuvant mitotane treatment in non-
metastatic ACC patients following complete tumor resection (53). We did a 
retrospective analysis of 152 patients who have not been included in previous studies. 
Of those, 100 patients underwent adjuvant mitotane therapy after initial surgery 
(mitotane group) and 52 were not treated with any adjuvant treatment following 
surgery (control group). The median RFS was 36.5 months (4-199) in the mitotane 
group and 21 months (4-180) in the control group (p<0.001). The difference in OS was 
not significantly different between treated and untreated patients; however, in the 
group of patients with either stage III ACC or ki67 index >10% adjuvant mitotane was 
associated with a significant increase of RFS (p=0.014) (53). Interestingly, hormone-
secreting ACC showed a higher ki67 index and this may explain why hormone 
secretion was a worse prognostic factor, as previously observed (54). In our 
experience, a low-dose mitotane regimen had acceptable toxicity and most patients 
were able to tolerate a long-term treatment. Therefore, this study is the first to support, 
although on a retrospective basis, the current recommendation of adjuvant mitotane 
therapy in ACC patients at high risk of recurrence following radical surgery (53). 
Controversy on adjuvant mitotane is deemed to continue unless results of prospective 
controlled studies become available. Therefore, we have launched the first 
randomized trial in an adjuvant setting for ACC, the ADIUVO study (http://www.adiuvo-
trial.org) under the endorsement of the European Network for the Study of Adrenal 
Tumors (ENSAT). The aim of the study is to assess the efficacy of adjuvant mitotane 
treatment in prolonging RFS in ACC patients at low-intermediate risk of recurrence. 
Results of ADIUVO are expected in 2020. 
A second prospective, randomized study on adjuvant therapy is currently under way. 
The ADIUVO-2 study aims to compare the efficacy of mitotane versus mitotane plus 
cisplatin and etoposide in preventing ACC recurrence following surgery in high-risk 
patients (ClinicalTrials.gov Identifier: NCT03583710). 
 
Practice Point 
• Mitotane reduces the risk of ACC recurrence following surgery; however, we are 
struggling to understand which patients are the best candidates for treatment. 
Research Agenda 
• Understand which patients truly respond to adjuvant mitotane therapy.  
• Develop alternative adjuvant therapies. 
 
            
Practical advices on management of adjuvant mitotane  
At the San Luigi Hospital, we start adjunctive mitotane treatment as soon as possible 
after surgery, at the very last within 3 months, in patients at high risk of recurrence, 
while low-risk patients have been enrolled in the ADIUVO trial (Figure 1). 
We do not institute mitotane therapy before surgery and we rarely combine mitotane 
with cisplatin therapy when we perceive the risk of recurrence as very high. We 
associate adjuvant mitotane with local radiotherapy, limiting the combined therapy in 
patients with R1 surgery. The problem with this approach, which has a sound 
rationale, is the increased toxicity of the combination that only fit patients can sustain.  
In our practice, we use a low-dose mitotane regimen, with a starting dose of 1 g daily 
with daily increments of 0.5 g (1 tablet) every 4 days until the maximal tolerated dose, 
usually less ≤ 6 g/daily (Table 1).  
We believe that a low-dose regimen is better tolerated with less impact on the quality 
of life of the patients, and this may eventually result in better compliance and more 
effective treatment. Although some experts advocate giving mitotane according to a 
high, rapidly escalating dose scheme (up to 6–9 g daily) (55), a recent survey of 
current practice in Italy showed that almost all expert centers use a low-dose regimen 
(56). By using this approach, mitotane was well tolerated and less than 5% of patients 
treated for at least 6 months had to discontinue permanently treatment for toxicity 
(early discontinuation was not recorded in the study). The trade-off with a very 
cautious drug escalation was the long time needed to attain therapeutic plasma 
concentrations of mitotane, averaging 8 months. Mitotane concentrations were 
significantly associated with the given dose and BMI, and women were treated with 
less doses (56). In analogy with the concept of time in target range used to evaluate 
the optimal exposure to warfarin therapy, we applied this measure to serial samplings 
of plasma mitotane in our series, and found that the time in target range was 
significantly associated with prolonged RFS. This result strengthens the value of 
mitotane monitoring and the concept of therapeutic mitotane concentrations in the 
adjuvant setting (56). 
The most common unwanted effects are gastrointestinal manifestations that appear 
early, independently on mitotane levels. They can be managed with temporary dose 
reduction, or delay of dose increments, and supportive therapy. Elevated γ-
glutamyltransferase levels are also frequently observed but are not actually 
troublesome unless values are exceedingly elevated. We usually do not reduce 
mitotane doses because GGT is elevated, given that this is the only altered liver 
function test. Clinically significant liver toxicity is characterized by a marked increase in 
transaminases and bilirubin, but is infrequently observed in the absence of 
predisposing conditions (43). We have seen rarely severe mitotane-induced hepatitis 
after few weeks of mitotane therapy, a time course that may suggest an idiosyncratic 
pathogenesis. Central neurologic toxicity (cerebellar symptoms, disturbed cognitive 
performance) is more closely associated with elevated mitotane concentrations (20 
mg/L) but subtler symptoms, such as memory impairment or attention deficit, may be 
observed in some patients even at lower drug concentrations (35, 37, 43). A great 
individual variability in the susceptibility to mitotane-related unwanted effects is 
apparent for causes that are still unknown.  
A general measure to deal with mitotane toxicity is a step down to the previously 
tolerated dose, or temporary drug withdrawal in the event of severe manifestations 
(Table 2). However, well-informed and motivated patients are able to cope with side 
effects and maintain compliance to treatment (2, 3, 57). To accomplish this task, it is 
important to establish a close patient–physician relationship to induce and maintain 
adherence to treatment. Patients seek advice frequently, also because their local 
physicians are unfamiliar with mitotane use and its attendant complications, and it is 
necessary to give a timely counseling to keep patients on treatment. It is impossible to 
get adequate compliance to treatment when acting solely as consultants, who see 
patients every some months. It is necessary to stay in contact with the patients and 
communicate with them in a timely manner to help them dealing with the drug-related 
unwanted effects. 
Because of the adrenolytic effect of mitotane, all patients should receive glucocorticoid 
replacement to prevent adrenal insufficiency (Table 2). Steroid doses are typically 
higher than in Addison’s disease, due to an enhanced metabolic clearance rate of 
glucocorticoids induced by mitotane (2, 3, 22, 57, 58). An inadequate treatment of 
adrenal insufficiency increases mitotane-related toxicity, particularly gastrointestinal 
side effects, and reduces tolerance (2, 3, 43). Mineralocorticoid supplementation is not 
mandatory in all patients because the zona glomerulosa is partly spared by the toxic 
effect of mitotane (43). Hormone measurement is of little help in guiding steroid 
replacement, although high renin values, particularly if in combination with elevated 
potassium and postural hypotension and fatigue, may herald the need of 
mineralocorticoid supplementation. Measurements of urinary free cortisol, or serum 
cortisol, are of limited value and also salivary cortisol does not add meaningful 
information (59). We use exceedingly high ACTH levels as a potential marker of 
insufficient glucocorticoid coverage, since mitotane also inhibits pituitary ACTH 
secretion, and ACTH levels in mitotane-treated patients are usually far less elevated 
than in classic Addison’s disease (59). 
Moreover, mitotane affects thyroid and gonadal function in a complex way by 
mechanisms that imply inhibition of pituitary TSH secretion (60). Mitotane 
administration is associated with low FT4 levels without a compensatory rise in TSH, 
an effect that becomes apparent early in the course of treatment in almost half of 
patients. We are currently suggesting thyroxin replacement in these patients, and 
sometimes further thyroxin dose increments are needed to keep levels into the normal 
range. We hope that thyroxin replacement may serve to reduce some mental effects 
(i.e. concentration deficits) that patients on mitotane complain of. However, we do not 
still have prove of a clear-cut benefit of this measure.  
In women, gonadal function is usually preserved and most female patients have 
regular cycles. We had indeed some conceptions, and even uneventful deliveries, 
during mitotane, despite that we strongly discourage to become pregnant. However, 
we do not recommend contraceptive pills, because they may be less effective and for 
the fear that estrogens may facilitate tumor progression (49). However, some women 
report disturbing spotting and heavy menstrual bleeding that are difficult to manage. 
Detection of ovarian cysts is frequent in such women and sometimes these lesions 
grow significantly and should be surgically treated (61).  
In the male sex, mitotane treatment may cause sexual dysfunction as a late unwanted 
effect, in about one third of patients, due to inhibition of testosterone secretion. 
Mitotane-induced increase in SHBG may confound interpretation of hormonal data 
(57). Sex steroid replacement may become necessary to treat hypogonadism but 
worsens gynecomastia (2, 3, 43, 57).  
Mitotane treatment is frequently associated with an alteration of the lipid panel, 
including elevation of both LDL and HDL cholesterol, which may reach remarkably 
high levels in some patients (57). The value of statin treatment is presently unclear 
(49). 
The availability of mitotane measurement across Europe, as a free service offered by 
the company distributing mitotane (info@lysodren-europe.com), gives the possibility to 
guide dose adjustments and prevent severe toxicity. Mitotane monitoring is key for an 
appropriate management of adjuvant treatment to reach mitotane concentrations that 
have been associated with therapeutic effect.    
The optimal duration of therapy remains undefined. The time to first recurrence after 
complete tumor resection is highly variable from some months to more than 10 years, 
but most recurrences occur within 2 years of primary surgery (2, 3, 28, 38, 43). In our 
own series, about 70% of relapses took place in the first 2 years of follow-up, whereas 
the frequency of late (>5 years) relapses was less than 1% (44). It is our current 
practice to accommodate patient preferences between a range of possibilities (2 to 5 
years of therapy) in a shared decision-making depending on tumor and patient 
characteristics. However, we are eager to prolong treatment, if well tolerated, in 
patients at elevated risk and we maintain treatment indefinitely after removal of a 
recurrence, or after radical surgery of stage IV ACC.   
 
Practice Points 
• Employ a low-dose, monitored mitotane regimen to reduce the risk of systemic 
toxicity and increase patient compliance. 
• Do a careful follow-up of patients on adjuvant mitotane and treat proactively the 
unwanted effects of treatment. 
Research Agenda 
• Understand what is the optimal duration of adjuvant mitotane therapy.  
• Understand what is the best supportive therapy to deal with drug toxicity. 
 
Selection of patients to adjuvant mitotane 
Despite the limits of the available evidence, adjuvant mitotane therapy is currently 
recommended in many expert centers whenever the patients present an elevated risk 
of recurrence (Figure 1). 
Differences do exist in the criteria used to define a high-risk condition. There is general 
agreement on stage I–II, complete (R0) resection and ki-67 <10% as markers of good 
prognosis, but opinions diverge whether stage III R0 ACC should be associated with 
high risk (49). By the ENSAT ACC staging system, stage III applies to locally invasive 
tumors characterized by infiltration in surrounding tissue, positive regional lymph 
nodes or a neoplastic thrombus in the vena cava or vena renalis (5). It is biologically 
plausible that tumor spread in regional lymph nodes or in the vein system may portend 
to higher risk of recurrence than local infiltration and it is our opinion that subgroups at 
different risk of recurrence do exist among stage III ACC. Infrequently, a stage IV 
ACC, defined by presence of distant metastases (5), may be completely resected and 
has to be considered at high risk of recurrence.  
The recent ESE-ENSAT guidelines have adopted the view that a low-risk condition is 
defined by stage I-II ACC, R0 and ki67 <10% (49). According to the guidelines, 
adjuvant mitotane is a non-mandatory option in patients at good prognosis, whereas a 
weak recommendation for adjuvant mitotane was done in the high-risk category (62).   
Recent data suggest that the proliferation activity of the tumor is the most important 
factor predicting risk of recurrence following R0 surgery. Assessment of the 
proliferation index ki-67 is currently used to assess proliferation, despite some 
problems to harmonize immunohistochemical readings among different pathologists. 
In a European multicentric study, a threshold value at 10% was found to separate 
patients at good or worse prognosis with a hazard ratio of recurrence of 1.042 per 
each % increase (31). Given the availability of a large patient cohort totaling more than 
500 patients, these are solid data confirming the view that tumor proliferation is a 
strong determinant of patient survival. The value of ACC proliferation has been already 
appreciated in smaller series by the use of mitosis count (28, 30), which is likely the 
single most predictive factor of Weiss score. Conversely, Weiss score per se does not 
clearly indicate the probability of tumor recurrence (63, 64).  
Resection status is another established adverse risk factor, being Rx (unknown), R1 
(microscopically positive margins) and R2 (macroscopically positive margins) 
associated with progressively reduced RFS irrespectively of other risk factors (2, 3, 43, 
64-66). However, it may be challenging to assess precisely resection status of a very 
large tumor, and pathologists infrequently report this parameter. 
A number of molecular markers might potentially emerge in the future as powerful 
outcome predictors (67), but none of them has yet found a place in current practice. 
The major problem is that they can be evaluated only in research labs with complex 
techniques that are not readily available. Moreover, molecular analyses are time-
consuming and still not apt to give results in a time frame suitable for the decision 
making process. A recent study showed that hypermethylation and silencing of G0S2 
is a hallmark of poor prognosis (68). Interestingly, assessment of G0S2 methylation 
can be done with a relatively simple and fast method that is potentially applicable in 
clinics. The combined assessment of G0S2 methylation with validated biomarkers 
(BUB1B-PINK1) may allow stratification of patients into different risk categories of 




• Use adjuvant mitotane therapy when the risk of ACC recurrence is perceived to 
be high. 
Research Agenda 
• Develop molecular markers that allow improved prognostication to do a better 
selection of patients in need of treatment.  
• Develop molecular markers that predict response to treatment.  
Mitotane for advanced adrenocortical carcinoma 
The management of ACC patients with metastatic disease is challenging and the 
prognosis is generally poor, since most patients are doomed to die of disease 
progression within 1-2 years. However, ACC is a heterogeneous disease and a subset 
of patients bearing less aggressive tumors may experience quite prolonged survival. 
Several prognostic factors such as time since initial surgery, presence of distant 
metastases, number of metastatic lesions and number of organs involved, and high 
tumor grade have been found to predict survival in patients with metastatic ACC (2, 3, 
49, 69). Moreover, studies indicated that overt cortisol excess is associated with a 
detrimental prognosis due to the associated morbidity (54). 
Treatment of advanced/metastatic patients may include as therapeutic tools loco-
regional approaches, such as surgery, radiofrequency ablation and 
chemoembolization, in patients with slowly progressive disease and low metastatic 
burden (25, 70, 71). Isolated loco-regional recurrence, or oligo-metastatic disease, 
may be managed by surgery whenever complete resection (R0) can be envisaged. In 
this context, an aggressive surgical approach may lead to improved survival (48). 
Conversely, tumor debulking offers little benefit and is conceivable only in patients with 
functional tumors not controlled by medical treatment. Loco-regional measures may 
synergize with systemic therapies to attain long-lasting tumor control in patients with 
less aggressive ACC (49).  
In presence of low-grade ACC with limited metastatic burden single-agent mitotane is 
a reasonable option (49) (Figure 2). Early studies assessing the efficacy of single-
agent mitotane reported a rate of objective tumor responses between 13% and 31% 
(37, 39, 72). However, most of the responses were of limited duration and complete 
responses were rarely observed. The outcome of these studies raised the concept of a 
“therapeutic range” of plasma mitotane concentrations that should be targeted in any 
patient with advanced/metastatic ACC. As a matter of fact, disease responses were 
mainly confined in patients attaining plasma mitotane concentration between 14 and 
20 mg/L (37, 39, 72). 
This concept has been validated more recently in a retrospective series of 127 patients 
receiving mitotane monotherapy for advanced ACC (73). In this study, the patients 
who reached a peak mitotane concentration >14 mg/L had longer progression-free 
survival (PFS) and OS than patients who did not. The rate of objective responses was 
also higher in patients with mitotane concentrations at target, even if some responses 
were observed with lower levels. Overall, a complete response was observed in 2.3% 
of patients, a partial response in 18.1%, and disease stabilization in 25.2%, 
respectively. Interestingly, objective tumor responses were as high as 30% in patients 
with either low tumor burden (<10 tumor lesions) or longer RFS after primary surgery 
(≥360 days). Although the OS was quite limited, being 18.5 months, mitotane 
monotherapy was able to attain long-lasting tumor control in a number of patients (73). 
Therefore, the study supports the concept that mitotane monotherapy is indicated in 
the management of patients with a low tumor burden and/or more indolent disease. 
Some experts actually suggest achieving even higher mitotane concentrations, if 
tolerated. 
Very recently, the outcome of single-agent monotherapy has been reported in 36 
patients with metastatic ACC treated at a single center. In this retrospective series, 
most patients progressed under treatment but a remarkable 8% complete response 
rate was observed. The responding patients had non-functioning tumors with a low-
volume disease (74). Although on a limited patient cohort, the study confirms that 
mitotane monotherapy may be effective in selected ACC patients. 
Besides its antitumor effect, mitotane is a strong inhibitor of adrenal steroidogenesis 
and it has a compelling indication in patients with endocrine symptoms, although the 
rate of success in controlling hormone excess is not well known (2, 3, 66).  
A classic management strategy implies mitotane monotherapy in the management of 
patients with a low tumor burden and/or more indolent disease, since mitotane is a 
slow acting drug (Figure 2). The latency of action of mitotane is related to the time 
needed to attain plasma concentrations at target. This particular feature of the drug 
translates in uncertainties concerning how long clinicians should wait to assess the 
efficacy of mitotane therapy, or its lack of. As a consequence, mitotane is continued 
almost indefinitely in many patients with advanced ACC lacking clear rules for its 
discontinuation.  
A recent study aimed to clarify this issue, evaluating the time until a partial response 
was attained in patients with metastatic ACC (75). A cohort of 68 patients who 
survived more than 24 months after diagnosis of stage IV ACC was retrospectively 
analyzed, including 57 patients treated with mitotane monotherapy and the remainders 
with mitotane associated to chemotherapy. In this selected cohort of long-term 
survivors, almost all objective responses were observed within 12 months from start of 
mitotane and this finding suggests that mitotane may be discontinued after that time if 
ACC continues to progress. The value of the therapeutic range was reaffirmed, since 
responses were more frequently and rapidly observed in patients attaining mitotane 
concentrations >14 mg/L. The association between response and target mitotane 
concentrations was less apparent when mitotane was used with chemotherapy (75). 
Chemotherapy plus mitotane is currently recommended for patients with highly 
proliferating and widespread disease (Figure 2). Chemotherapy in the management of 
advanced ACC is usually administered in association with mitotane not only in patients 
with de novo stage IV ACC, but also in patients with disease progression to mitotane 
therapy, when mitotane is usually maintained, if tolerated (49). Despite that combining 
mitotane with classic cytotoxic agents is a commonly used strategy, the evidence 
supporting a synergism between mitotane and chemotherapy is weak. However, 
indirect comparisons of response rates obtained in non-randomized phase II trials 
showed greater activity of chemotherapy regimens including mitotane (49). Up to now, 
no randomized study has tested prospectively the efficacy of mitotane plus 
chemotherapy versus mitotane alone.  
The first prospective multinational trial on treatment of ACC (FIRM-ACT) ever 
published has recently set a standard of care for advanced/metastatic ACC (13). In 
this trial, the association of etoposide, doxorubicin and cisplatin plus mitotane (EDP-M) 
was found to be superior to streptozotocin plus mitotane in terms of disease response 
rate and PFS. On the bases of the results of this study, the EDP-M scheme is actually 
recommended as the standard approach for ACC patients by ESE-ENSAT guidelines 
(49). The efficacy of EDP-M in this multinational Phase III trial, however, was modest: 
the response rate was low (23%), and the median PFS and OS were of only 5 and 
14.8 months, respectively. The FIRM-ACT trial also provided some evidence that 
mitotane levels at target could improve patient outcome (13). 
Mitotane efficacy, as previously discussed, is not immediate, and the so-called 
therapeutic range is usually attained within 2-3 months, so disease progression may 
precede the time when mitotane levels are at target. Chemotherapy may be effective 
in the first weeks of therapy and this is a pragmatic point favoring a functional 
synergism between mitotane and chemotherapy in patients with aggressive disease. 
On the other hand, mitotane may be also important for the long-term disease control. 
In the randomized trial FIRM-ACT, a few patients were free of progression after 4 
years in both EDP-M and SZ-M arms. In these patients, mitotane could have 
contributed to the long-term delay of disease progression. In our experience, a few 
patients achieve disease response with the EDP-M regimen and then a long-lasting 
disease control by sustained mitotane therapy. The best outcome is observed in 
patients whose disease become surgically treatable following tumor shrinkage induced 
by chemotherapy and are able to attain a R0 resection, and then undergo chronic 
mitotane treatment. However, the toxicity associated with the EDP-M scheme is 
important and only fit patients can sustain treatment. In case of compromised 
conditions and/or elder patients, we opt for mitotane monotherapy, or to mitotane plus 
cisplatin as an alternative to the whole EDP scheme. 
 
Practice Points 
• Use mitotane monotherapy in patients with limited tumor burden, and/or slow 
progression rate. 
• Use mitotane plus chemotherapy (EDP) in patients with widespread disease 
and/or rapid progression rate, or when ACC progress to mitotane monotherapy. 
• Consider associating loco-regional measures to systemic mitotane therapy to 
improve disease control. 
Research Agenda 
• Develop better treatment of advanced ACC.  
• Develop molecular markers that predict response to treatment.  
 
Conclusion 
Whenever ACC is completely removed, we should face the dilemma to use adjuvant 
therapy or not. In our opinion, adjuvant mitotane is the preferable approach in most 
cases, because the majority of patients referred to our institution following surgery for 
ACC show an elevated risk of recurrent disease. A better understanding of factors that 
influence prognosis and response to treatment (68) will help in stratifying patients 
according to their probability of benefiting from adjuvant mitotane, with the aim of 
sparing unnecessary toxicity to patients who are less likely to respond.  
The strategy of treatment of advanced ACC is chosen considering a number of 
prognostic factors (tumor burden, type of progression, secretion, proliferation index) 
and the patient conditions. If a patient is fit and carries poor prognostic factors, we 
recommend the EDP-M regimen. Patients at perceived good prognosis may be treated 
with mitotane monotherapy and EDP is added on in case of disease progression. 
However, until significant advancements will take place, we have to deal with 
uncertainty using our best clinical judgment and personal experience in the clinical 
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Figure-1.  Management of ACC patients following surgery with radical intent. 
Figure-2. Management of ACC patients with advanced or recurrent disease not 
amenable of surgery with radical intent. 
 
